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High Risk for 
Tuberculosis 
in Hospital 
Physicians, Peru
To the Editor: Occupational ex-
posure to Mycobacterium tuberculo-
sis poses a major risk to medical staff
worldwide. In areas of high tuberculo-
sis (TB) incidence such as Peru (228–
364 cases/100,000 [1,2]), the risk for
hospital workers may be 40 times
greater than that for the general popu-
lation (3). Prospective studies to eval-
uate the precise occupational risk to
medical staff in developing countries
with a high incidence of TB disease
are lacking. We evaluated the inci-
dence of TB skin test (TST) conver-
sion and TB disease in interns and
residents in a teaching hospital in
Lima, Peru.
Our study included 54 medical
interns and 45 residents who began
training in April 2000 at the Carrión
Hospital, where all patients with TB
are housed in wards without respira-
tory isolation. Each study participant
had an initial evaluation before begin-
ning hospital training. TST and chest
radiographs were performed on entry
into the study and 11 months later.
TSTs were performed by the standard
Mantoux technique, that is, intrader-
mal injection of purified protein deriv-
ative (5 tuberculin units/0.1 mL)
(Connaught Ltd., Ontario, Canada).
Indurations were measured 48–72
hours later. A positive result was
defined as an induration >10 mm. TST
conversion from a negative to a posi-
tive result was defined as an increase
of >10 mm in induration, according to
criteria of the Centers for Disease
Control and Prevention (CDC) (4).
Every 3 months, physicians were
screened for signs and symptoms of
TB, and at 9 months they were inter-
viewed for risk factors such as area of
service, contact with active TB cases,
and usage of an approved mask (N95
type). All statistical analyses were per-
formed by using STATA 7.0 (Stata
Corporation, College Station, TX).
Ninety-eight interns and residents
(mean age 29.2 years ± 4.1 SD) were
evaluated with an initial TST. One res-
ident declined participation. Fifty-nine
percent of the participants were TST
positive at the initial evaluation. The
presence of one BCG scar was not
correlated with initially positive TST
results. However, positivity in partici-
pants with two or more BCG scars
was significantly higher (odds ratio
8.6; 95% confidence interval 1.8 to
79.5; p=0.002). Approximately two
thirds (66/97) of participants recalled
contact with an active TB case before
the study period. All eight physicians
whose relatives had been treated for
TB were initially TST positive
(p=0.01). 
Of the 40 physicians who were
negative at the initial TST, 35 (88%)
were tested again 11 months later.
Five residents did not have a TST. In
one of these, an intensive-care resi-
dent, active pleural TB developed; the
other residents remained well after 1
year. Five of the 35 physicians retested
after 1 year had converted; 1 of these 5
also had pleural TB. Thus, 2 (5%) of
40 initially TST-negative physicians
had acquired active TB, for an annual
incidence of 2% (2/98).
The annual TST conversion rate
for TST-negative physicians was 17%
(6/36, including the TB patient with-
out a follow-up TST). In addition, 11
(31%) of 35 persons with an initial
negative TST result were positive
(>10 mm) on second testing, but the
increase in induration was <10 mm.
No significant differences were
observed between conversion rates in
interns and residents.
Ninety-five physicians responded
to the questionnaire on mask use. Over
9 months, 87 (92%) of 95 trainees had
treated patients with active TB (mean
number of cases 14 ± 14 SD). In the
TST-negative group who were
retested, physicians who converted
had significantly more contact with
patients known to have active TB than
physicians who did not convert (24 ±
11 SD, respectively, vs. 8 ± 7 SD,
p=0.003). During this period of fol-
low-up, no physician was aware of his
having been exposed to a TB patient
in the physician’s home. No other risk
factors (age, gender, area of service,
participation in intubation or autopsy,
approved mask usage, number of BCG
scars) differed significantly between
converters and nonconverters.
No physician reported consistently
using a mask when examining patients
with suspected TB or respiratory
symptoms. Only 7 (7.4%) of 95 physi-
cians reported that they consistently
used a mask when examining active
TB cases. Furthermore, 51 (54%) phy-
sicians never used a mask when exam-
ining a patient. Of the six physicians
who converted, two reported never
having used a mask, two reported
mask use when working with diag-
nosed TB patients, and two reported
sometimes using masks when working
with TB patients. 
Physicians exposed to a large
number of TB cases at a public hospi-
tal had a 17% annual TST conversion
rate. This rate is much higher than the
3% conversion rate in people living in
a poor, overcrowded urban setting (2).
Studies in industrialized countries
show annual conversion rates ranging
from 0.1% to 2% in unexposed
employees and 1% to 10% in highly
exposed health-care workers (5). 
Our study also demonstrated a high
incidence of symptomatic TB in Peru-
vian physicians. The 2% rate reported
in this study is 10–15 times higher than
that reported for the general population
(6) and is similar to that in nurses car-
ing for advanced TB patients in
England during the 1930s (7).
The high TST conversion rate in
physicians is most likely due to expo-
sure to TB in the hospital. Boosting
may at times produce large reactions
and in all serial TB studies will be a
potential confounder (8). To decrease
the likelihood that boosting had
occurred, we used stringent CDC cri-
teria for conversion. The high inci-
dence of active TB in the physicians
strongly suggests that most conver-
sions were due to TB transmission
rather than boosting. LETTERS
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Additionally, the high conversion
rate (two of five) in those who
reported consistent mask use when
caring for active TB cases may sug-
gest overreporting of mask use, poor
adjustment of the mask, contact with
unsuspected active cases (9), or con-
tact with a contaminated environment.
This high TST conversion rate and
incidence of TB demonstrate the inad-
equacy of hospital infection control
measures. In Peru, both unsuspected
active TB and multidrug-resistant TB
are highly prevalent (9). Rapid detec-
tion and respiratory isolation of
patients with active or suspected TB
are rarely practiced. 
In conclusion, Peruvian physicians
have an extremely high risk of TST
conversion and active TB. Hospitals in
developing countries need to design
and implement effective and appropri-
ate infection control measures such as
appropriate mask usage, sputum test-
ing, and rapid reporting of MTB
smears of all patients with respiratory
symptoms, as well as respiratory con-
trol for smear-positive TB cases (10).
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First Documented 
Human Rickettsia 
aeschlimannii 
Infection
To the Editor: Rickettsia aeschli-
mannii, which was first isolated from
Hyalomma marginatum ticks collected
in Morocco in 1997 (1), has also been
found in H. marginatum ticks from
Zimbabwe, Niger, and Mali (2). For
the past 3 years, we have included this
species in the panel of rickettsiae for
which sera from patients with sus-
pected tickborne diseases are routinely
tested. This procedure allowed us to
document, by polymerase chain reac-
tion (PCR) amplification and sero-
logic testing, the first case of R.
aeschlimannii human infection, which
occurred in a patient returning from
Morocco.
This 36-year-old man traveled to
Morocco in August 2000. On return-
ing to France, he noticed a vesicular
lesion of the ankle, which became
necrotic and resembled the typical
“tâche noire” of Mediterranean spot-
ted fever (3). He became ill with fever
of 39.5°C and a generalized maculo-
papular skin rash. Laboratory tests
showed a normal blood cell count but
moderately increased transaminases.
An early serum specimen was tested
to confirm the diagnosis of Mediterra-
nean spotted fever. By microimmuno-
fluorescence, the patient’s serum had
immunoglobulin G and M titers of
1:32 and 1:16, respectively, against R.
aeschlimannii; 0 and 1:16 against R.
conorii, R. africae, R. slovaca, R. hel-
vetica, and R. massiliae; and 0 and 1:8
against “R. mongolotimonae.” West-
ern blot results showed that the
patient’s serum reacted more inten-
sively with R. aeschlimannii proteins
than with those of the other tested
rickettsiae. Attempted PCR amplifica-
tion of a 630-nt portion of the rickett-
sial ompA gene (nt 70 to 701) (4) from
the early serum specimen yielded a
product of the expected size. The
sequence of this amplicon allowed the
identification of R. aeschlimannii with
100% homology. The patient was
treated with doxycycline, 200 mg
daily for 1 week, and rapidly recov-
ered.
This case is the first documented
infection caused by R. aeschlimannii,
a  Rickettsia that had been isolated
only from Hyalomma marginatum
ticks from Africa. In our patient, its
pathogenic role was demonstrated by
PCR, a technique that has also proven
useful in identifying other new rickett-
sial diseases, including infections with